Aurora Kinases

A family of highly conserved serine-threonine kinases that are involved in the regulation of MITOSIS. They are involved in many aspects of cell division, including centrosome duplication, SPINDLE APPARATUS formation, chromosome alignment, attachment to the spindle, checkpoint activation, and CYTOKINESIS.

Also Known As:

Networked: 656 relevant articles (33 outcomes, 125 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Liu, Quentin: 11 articles (05/2022 - 03/2008)
2.	Yan, Min: 10 articles (05/2022 - 03/2008)
3.	Ulisse, Salvatore: 10 articles (11/2017 - 07/2006)
4.	Baldini, Enke: 9 articles (10/2016 - 07/2006)
5.	Hsieh, Hsing-Pang: 8 articles (01/2022 - 03/2009)
6.	Mahadevan, Daruka: 8 articles (12/2018 - 01/2003)
7.	Coumar, Mohane Selvaraj: 8 articles (07/2016 - 03/2009)
8.	D'Armiento, Massimino: 8 articles (05/2016 - 07/2006)
9.	Moll, Jürgen: 8 articles (09/2012 - 09/2007)
10.	Carpinelli, Patrizia: 7 articles (12/2021 - 09/2007)

Related Diseases

1.	Neoplasms (Cancer) 08/08/2017 - "Aurora kinases play a crucial role in mitosis and selective inhibitors might provide an effective therapeutic treatment for cancer. " 04/01/2011 - "In conclusion, our data demonstrated that Aurora kinase inhibition is effective in reducing cell growth and inducing apoptosis of ATC in vitro and tumor growth and vascularity in vivo. " 01/01/2010 - "Therefore, Aurora kinase inhibitors should be useful in the treatment of cancers. " 10/23/2008 - "PTTG1 knockdown is therefore a potential approach to improve the efficacy of tumor Aurora kinase inhibitors." 09/01/2019 - "Aurora kinases have shown great promise in treating tumors. "
2.	Ovarian Neoplasms (Ovarian Cancer) 09/01/2008 - "The role of Aurora kinase inhibition in ovarian cancer merits further investigation in clinical trials." 10/01/2020 - "Aurora kinases in ovarian cancer." 11/01/2017 - "Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer." 12/11/2008 - "We show that inhibition of the Aurora kinases prevents phosphorylation of a mitotic marker and demonstrate a dose-dependent increase of apoptosis in treated ovarian cancer cells. " 02/01/2006 - "The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment."
3.	Leukemia 06/01/2007 - "Taken together, inhibition of Aurora kinases may be a promising treatment strategy for individuals with leukemia." 08/21/2018 - "In this study, we investigated whether inhibiting Aurora kinase can reduce the viability of Ph+ leukemia cells. " 11/28/2016 - "This study aimed to identify new molecular targets for Aurora kinase inhibition in human leukemia cells using quantitative proteomic analysis followed by verification experiments. " 01/29/2015 - "This review will describe the functions of each Aurora kinase, summarize their involvement in leukemia and discuss inhibitor development and efficacy in leukemia clinical trials. " 01/01/2014 - "A comparative analysis of these agents in cytotoxicity and target modulation analyses against a panel of leukemia cells provides novel insights into the unique mechanisms and codependent activity pathways involved in targeting Aurora kinases, constituting a distinctive preclinical experimental framework to identify appropriate agents and combinations in future clinical studies. "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 06/01/2007 - "A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia." 10/01/2008 - "Aberrant expression of Aurora kinases and inactivation of wild-type p53 by Mdm2 overexpression are frequent molecular events in acute myelogenous leukemia (AML), and preclinical data for inhibition of Aurora kinases or Mdm2 are promising. " 10/01/2008 - "Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia." 05/01/2008 - "Aurora kinase gene expression profiles were assessed in 101 samples from patients with acute myeloid leukemia. " 07/01/2017 - "Aurora kinases are involved in the pathophysiology of several cancers including acute myeloid leukemia (AML). "
5.	Polyploidy 11/01/2013 - "Thus, our results revealed that inhibition of mTOR pathway decreased the glycolytic metabolism of the polyploidy cells, and increased the efficacy of Aurora kinases inhibitors, providing a novel approach of combination treatment in AML." 05/01/2014 - "Deficiency in PUMA increased polyploidy, improved cell survival, and abrogated mitochondria-mediated apoptosis induced by aurora kinase inhibitors. " 01/01/2017 - "CyclinG1 Amplification Enhances Aurora Kinase Inhibitor-Induced Polyploid Resistance and Inhibition of Bcl-2 Pathway Reverses the Resistance." 08/01/2014 - "Cells sensitive to Aurora kinase inhibitors underwent apoptosis at an IC50 of ∼10-30 nM and displayed a phenotype of Aurora-A inhibition, whereas cells resistant to Aurora kinase inhibitors (with an IC50 more than 10 μM) accumulated polyploidy, which may have resulted from Aurora-B inhibition. " 01/01/2013 - "Mechanistic analyses revealed that inhibition of aurora kinases induced polyploidy and the ATM/Chk2 DNA damage response, which mediated senescence and a NF-κB-related, senescence-associated secretory phenotype (SASP). "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Mitogen-Activated Protein Kinase Kinases (MEKs)
3.	Antineoplastic Agents (Antineoplastics)
4.	tozasertib
5.	Aurora Kinase A
6.	Proteins (Proteins, Gene)
7.	Histone Deacetylase Inhibitors
8.	Histones (Histone)
9.	4- (4- (N- benzoylamino)anilino)- 6- methoxy- 7- (3- (1- morpholino)propoxy)quinazoline
10.	Imatinib Mesylate (Gleevec)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Radiotherapy
4.	Re-Irradiation
5.	Precision Medicine